 | Your browser does not display parts of our website correctly. We use the latest technology available to provide you with a high quality experience; please upgrade your browser to its latest version to view the contents properly: |
Teva Pharmaceutical Industries Limited (TEVA) develops, manufactures, markets, and distributes generic medicines and a portfolio of specialty medicines worldwide.
It operates through two segments, Generic Medicines and Specialty Medicines.
The Generic Medicines segment offers sterile products, hormones, narcotics, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments, and creams.
This segment also develops, manufactures, and sells active pharmaceutical ingredients. The Specialty Medicines segment provides branded specialty medicines for use in central nervous system and respiratory indications, as well as the women's health, oncology, and other specialty businesses. Its products in the central nervous system area comprise Copaxone for multiple sclerosis; Azilect for the treatment of Parkinsons disease; and Nuvigil for the treatment of excessive sleepiness associated with narcolepsy and certain other disorders.
This segments products in the respiratory market include ProAir, ProAir Respiclick, QVAR, Duoresp Spiromax, Qnasl, Braltus, Cinqair/Cinqaero, and Aerivio Spiromax for the treatment of asthma and chronic obstructive pulmonary disease, as well as Treanda/Bendeka, Granix, Trisenox, Lonquex, and Tevagrastim/Ratiograstim products in the oncology market.
This segment also offers a portfolio of products in the womens health category, which includes ParaGard, Plan B One-Step, and OTC/Rx, as well as other products.
Shares have formed a bullish "flag" following several positive developments for the company. First, the company annunced a new CEO which was received very well with the market. The company agreed to sell the remaining assets of its specialty global women’s health business for $1.38B to reduce its debt. The news has sent the shares into this bullish formation which should push the shares higher.
52-Weeks Trading Range: $15.22 - $51.15
Entry Point: $17.15
Stop Loss: $16.20
Target Price: $18.87
TEVA closed at $16.25.
